Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
Editor updated for a page on volunteer assignments
 
(30 intermediate revisions by 3 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br />
__TOC__
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big>
Line 16: Line 17:
!'''Date of Last Editor Review'''
!'''Date of Last Editor Review'''
!'''Notes'''
!'''Notes'''
|-
|
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]]
|[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]]
Line 22: Line 44:
|6/25/2023
|6/25/2023
|
|
|PENDING
|COMPLETE
|
|
|Laveniya Satgunaseelan (LS)
|Laveniya Satgunaseelan (LS)
Line 30: Line 52:
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]]
|Disease
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|Riley Lochner (trainee);
Shashi Shetty (mentor)
|6/7/2022
|6/7/2022
|
|
Line 41: Line 64:
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|Disease
|Disease
|Meenakshi Mehrotra
|Jieying Wu
|
|11/18/2025
|
|01/15/2026
|PENDING
|PENDING
|
|
|LS
|LS
|
|
|Moved from "Glioblasoma, IDH-wildtype" to new page; 2021 template added
|Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added
|-
|-
|[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]]
|[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]]
Line 55: Line 78:
|6/27/2023
|6/27/2023
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 85: Line 108:
|[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]]
|[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]]
|Disease
|Disease
|Scott Smith
|5/3/2024
|
|
|PENDING - email reminder 9/4/2025
|
|
|
|LS
|
|
|
|
|
|
|
Line 96: Line 119:
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]]
|Disease
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|Laveniya Satgunaseelan
|
|
|
|12/06/2025
|PENDING
|PENDING
|
|
Line 115: Line 138:
|
|
|2021 template added
|2021 template added
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]]
Line 136: Line 170:
|
|
|
|
|2021 template added
|
|-
|-
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Jeremy Pulvers
|9/13/2022<br />
|
|
|PENDING
|<br />
|
|
|
|
|LS
|LS
Line 162: Line 196:
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]]
|Disease
|Disease
|Wahab Khan
|15/04/2025
|
|
|
|PENDING - email reminder 9/4/2025
|
|
|
|
|LS
|LS
Line 225: Line 259:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]]
Line 294: Line 339:
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]]
|Disease
|Disease
|Laveniya Satgunaseelan
|9/11/2024
|
|
|
|COMPLETE
|
|8/7/2025
|
|LS
|
|LS
|
|Used for testing 9/2024 somatic template
|
|
|-
|-
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]]
Line 335: Line 380:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]]
Line 445: Line 501:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]]
Line 467: Line 534:
|
|
|
|
|-
|
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]]
|[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]]
Line 500: Line 588:
|
|
|
|
|-
|
====CHAPTER 4 (EMBRYONAL TUMOURS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]]
|Disease
|Disease
|Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|Lisa Lansdon, PhD (LGG trainee just finished);
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|9/20/21
|
|
Line 525: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|MS
|
|
|
|
|
|-
|
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]]
Line 621: Line 742:
|
|
|
|
|-
|
====CHAPTER 5 (PINEAL TUMOURS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Pineocytoma|Pineocytoma]]
|[[CNS5:Pineocytoma|Pineocytoma]]
Line 632: Line 774:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]]
Line 645: Line 798:
|-
|-
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|Disease
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|5/15/2026
|Pending
|
|LS
|
|
|-
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|Disease
|Disease
|
|
Line 655: Line 819:
|
|
|-
|-
|[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]]
|[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]]
|Disease
|Disease
|
|
Line 666: Line 830:
|
|
|-
|-
|[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]]
|Disease
|
|
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Schwannoma|Schwannoma]]
|[[CNS5:Schwannoma|Schwannoma]]
Line 731: Line 905:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
Line 753: Line 938:
|
|
|
|
|-
|
====CHAPTER 7 (MENINGIOMA)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Meningioma|Meningioma]]
|[[CNS5:Meningioma|Meningioma]]
Line 764: Line 970:
|
|
|
|
|-
|
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
Line 819: Line 1,046:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
Line 885: Line 1,123:
|
|
|
|
|-
|
====CHAPTER 9 (MELANOCYTIC TUMOURS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]]
|[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]]
Line 907: Line 1,166:
|
|
|
|
|-
|
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)====
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
|[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]]
|[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]]
Line 918: Line 1,198:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]]
Line 983: Line 1,274:
|MS
|MS
|
|
|2021 template added
|2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"?
|-
|-
|[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]]
|[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]]
Line 1,028: Line 1,319:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
Line 1,051: Line 1,353:
|
|
|-
|-
|[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]]
|Disease
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]]
|[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]]
|Disease
|Disease
|
|
Line 1,073: Line 1,385:
|
|
|-
|-
|[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]]
|Disease
|
|
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]]
|[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]]
|Disease
|Disease
|
|
Line 1,095: Line 1,417:
|
|
|-
|-
|[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]]
|[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]]
|Disease
|Disease
|
|
Line 1,106: Line 1,428:
|
|
|-
|-
|[[CNS5:Pituitary_blastoma|Pituitary blastoma]]
|[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]]
|Disease
|Disease
|
|
Line 1,117: Line 1,439:
|
|
|-
|-
|[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]]
|[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]]
|Disease
|Disease
|
|
Line 1,128: Line 1,450:
|
|
|-
|-
|[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]]
|[[CNS5:Pituitary_blastoma|Pituitary blastoma]]
|Disease
|Disease
|
|
Line 1,139: Line 1,461:
|
|
|-
|-
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
!'''Disease'''
|Disease
!'''Page Type'''
|Ngoni Faya (trainee) + Madina Sukhanova
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
|
====CHAPTER 13 (METASTASES TO THE CNS)====
|
|
----
|
|
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
----
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|Disease
|
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]]
|Disease
|Disease
|
|
Line 1,172: Line 1,504:
|
|
|-
|-
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
|[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]]
|Disease
|Disease
|
|
Line 1,183: Line 1,515:
|
|
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|
|
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)====
|
----
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|-
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|Disease
|Disease
|
|
Line 1,205: Line 1,569:
|
|
|-
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|Disease
|
|
Line 1,215: Line 1,590:
|
|
|
|
|-
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]]
|Disease
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS
|N/A
|
|N/A
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|Disease
|Disease
|Jennifer Laffin
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|8/22/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS/MS
|N/A
|
|N/A
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
Line 1,273: Line 1,681:
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|[[CNS5:DICER1_syndrome|DICER1 syndrome]]
|Disease
|Disease
|Jennie Thurston
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|7/2/2023
|N/A
|
|N/A
|PENDING
|N/A
|
|N/A
|LS
|N/A
|
|N/A
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content.
|N/A
|-
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
Line 1,314: Line 1,722:
|
|
|
|
|-
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
Line 1,328: Line 1,747:
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|-
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
Retrieved from "https://test.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"